Aravive launches ~$10M stock and warrant offering

Mar. 30, 2022 8:12 AM ETAravive, Inc. (ARAV)By: Preeti Singh, SA News Editor
  • Aravive (NASDAQ:ARAV) has announced a ~$10M registered direct offering priced at-the-market under Nasdaq rules.
  • The oncology firm entered into definitive agreements with a single healthcare-focused institutional investor and Eshelman Ventures to offer 4.85M shares of its common stock and warrants to purchase up to 4.85M shares of common stock.
  • The purchase price per share and accompanying warrant is $2.005 for the institutional investor and $2.325 for Eshelman Ventures.
  • The warrants to be issued to the institutional investor will be immediately exercisable at $1.88 per share and will expire five years following the issuance date.
  • The warrants to be issued to Eshelman Ventures will be exercisable upon the approval by the stockholders of the company of previously issued securities (at $2.20/share) and will expire five years following the issuance date.
  • Gross proceeds are expected to be ~$10M; net proceeds will support clinical development of batiraxcept in platinum resistant ovarian cancer and clear cell renal cell carcinoma.
  • Offering is expected to close on Mar. 31, 2022.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.